Gene Therapy Restores Vision in Blindness Study

A research team in South Korea has achieved something once thought impossible: reversing vision loss caused by a genetic mutation in the mitochondria.

The scientists successfully treated Leber's hereditary optic neuropathy (LHON), a disease that steals sight from young people, typically men in their teens and twenties. The condition causes rapid vision loss and eventual blindness as optic nerve cells die.

LHON affects an estimated 30,000 to 50,000 people worldwide. It passes from mothers to children through defective mitochondrial DNA, the genetic material that lives outside a cell's nucleus.

For years, doctors had no way to fix the root problem. Traditional gene-editing tools like CRISPR couldn't reach inside the mitochondria where the mutations hide. The only approved medication, idebenone, offers temporary support but doesn't stop the disease.

The research team from Korea University College of Medicine partnered with Seoul National University and Edgene Co. to crack this challenge. They first created mice with the exact mutation that causes 70% of human LHON cases.

Then came the breakthrough. The scientists used a new gene-editing technology called TALED, delivered through a modified virus injected into the eye. The treatment successfully corrected the mutation in retinal ganglion cells, the neurons that die in LHON patients.

The results published in Nature Communications showed dramatic improvements. Retinal thickness returned to normal levels. Cell counts recovered. Most importantly, the mice regained visual function measured through standard eye tests.

The team didn't stop with mice. They applied the same treatment to cells taken from actual LHON patients and restored normal energy production and cellular function.

Why This Inspires

This research represents more than scientific achievement. It offers concrete hope to families who have watched their children lose sight with no treatment options.

The technology could extend beyond LHON to other mitochondrial diseases, which affect roughly 1 in 5,000 people. For the first time, scientists have shown they can safely edit mitochondrial genes in living tissue.

Lead researcher Professor Hyunji Lee called it "the world's first study to demonstrate therapeutic efficacy of gene editing in a living model of mitochondrial disease." The team is now working toward human clinical trials.

Young people diagnosed with LHON may soon have something previous generations never had: a cure that addresses the disease at its genetic source.